Metformin decreases serum 8-hydroxy-2′-deoxyguanosine levels in polycystic ovary syndrome

Fertility and Sterility

Volumn 99, Issue 2, 2013, Pages 593-598

  Sova, Henri ^a   Puistola, Ulla ^a   Morin Papunen, Laure ^a   Karihtala, Peeter ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

8 OHdG; metformin; oxidative stress; polycystic ovary syndrome; reactive oxygen species

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; METFORMIN; PLACEBO;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MULTICENTER STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION;

ADULT; BIOLOGICAL MARKERS; DEOXYADENOSINES; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME;

EID: 84873322530     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2012.10.013     Document Type: Article

References (47)

1. L. Leeman, and U. Acharya The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence J Obstet Gynaecol 29 2009 467 472
2. T. Tsilchorozidou, C. Overton, and G.S. Conway The pathophysiology of polycystic ovary syndrome Clin Endocrinol (Oxf) 60 2004 1 17
3. R. Mathur, C.J. Alexander, J. Yano, B. Trivax, and R. Azziz Use of metformin in polycystic ovary syndrome Am J Obstet Gynecol 199 2008 596 609
4. X. Hou, J. Song, X.N. Li, L. Zhang, X. Wang, L. Chen, and Y.H. Shen Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway Biochem Biophys Res Commun 396 2010 199 205
5. P. Karihtala, and Y. Soini Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies APMIS 115 2007 81 103
6. A. Valavanidis, T. Vlachogianni, and C. Fiotakis 8-hydroxy-2′- deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27 2009 120 139
7. M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser Free radicals and antioxidants in normal physiological functions and human disease Int J Biochem Cell Biol 39 2007 44 84
8. F. González, N.S. Rote, J. Minium, and J.P. Kirwan Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome J Clin Endocrinol Metab 91 2006 336 340
9. J.R. Palacio, A. Iborra, Z. Ulcova-Gallova, R. Badia, and P. Martínez The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients Clin Exp Immunol 144 2006 217 222
10. J. Pourova, M. Kottova, M. Voprsalova, and M. Pour Reactive oxygen and nitrogen species in normal physiological processes Acta Physiol (Oxf) 198 2010 15 35
11. H. Kasai Chemistry-based studies on oxidative DNA damage: formation, repair, and mutagenesis Free Radic Biol Med 33 2002 450 456
12. M.S. Cooke, M.D. Evans, R. Dove, R. Rozalski, D. Gackowski, and A. Siomek DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine Mutat Res 1 2005 58 66
13. L. Morin-Papunen, A.S. Rantala, L. Unkila-Kallio, A. Tiitinen, M. Hippeläinen, and A. Perheentupa Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial J Clin Endocrinol Metab 97 2012 1492 1500
14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 19 2004 41 47
15. G. Gennarelli, J. Holte, L. Berglund, C. Berne, M. Massobrio, and H. Lithell Prediction models for insulin resistance in the polycystic ovary syndrome Hum Reprod 15 2000 2098 2102
16. M.C. Peoples, and H.T. Karnes Recent developments in analytical methodology for 8-hydroxy-2′-deoxyguanosine and related compounds J Chromatogr B Analyt Technol Biomed Life Sci 827 2005 5 15
17. J. Sheridan, L.M. Wang, M. Tosetto, K. Sheahan, J. Hyland, and D. Fennelly Nuclear oxidative damage correlates with poor survival in colorectal cancer Br J Cancer 100 2009 381 388
18. P. Karihtala, Y. Soini, L. Vaskivuo, R. Bloigu, and U. Puistola DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma Int J Gynecol Cancer 19 2009 1047 1051
19. D. Murtas, F. Piras, L. Minerba, J. Ugalde, C. Floris, and C. Maxia Nuclear 8-hydroxy-2′-deoxyguanosine as survival biomarker in patients with cutaneous melanoma Oncol Rep 23 2010 329 335
20. H. Sova, A. Jukkola-Vuorinen, U. Puistola, S. Kauppila, and P. Karihtala 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer Br J Cancer 102 2010 1018 1023
21. S. Correia, C. Carvalho, M.S. Santos, T. Proença, E. Nunes, and A.I. Duarte Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes Med Chem 4 2008 358 364
22. G. Formoso, E.A. De Filippis, N. Michetti, P. Di Fulvio, A. Pandolfi, and T. Bucciarelli Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects Diabetes Metab Res Rev 24 2008 231 237
23. M. Yilmaz, N. Bukan, G. Ayvaz, A. Karakoç, F. Törüner, and N. Cakir The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome Hum Reprod 20 2005 3333 3340
24. P. Ovesen, J. Moller, H.J. Ingerslev, J.O. Jørgensen, A. Mengel, and O. Schmitz Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome J Clin Endocrinol Metab 77 1993 1636 1640
25. L.C. Morin-Papunen, I. Vauhkonen, R.M. Koivunen, A. Ruokonen, and J.S. Tapanainen Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome Hum Reprod 15 2000 1266 1274
26. S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, and Y. Nakajima Increased oxidative stress in obesity and its impact on metabolic syndrome J Clin Invest 114 2004 1752 1761
27. J.F. Keaney Jr., M.G. Larson, R.S. Vasan, P.W. Wilson, I. Lipinska, and D. Corey Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study Arterioscler Thromb Vasc Biol 23 2003 434 439
28. K. Sebeková, V. Somoza, M. Jarcusková, A. Heidland, and L. Podracká Plasma advanced glycation end products are decreased in obese children compared with lean controls Int J Pediatr Obes 4 2009 112 118
29. P. Karihtala, and U. Puistola Hypoxia and oxidative stress in the pathogenesis of gynecological cancers and in therapeutical options Curr Cancer Ther Rev 7 2011 37 55
30. M.S. Cooke, M.D. Evans, M. Dizdaroglu, and J. Lunec Oxidative DNA damage: mechanisms, mutation, and disease FASEB J 17 2003 1195 1214
31. A. Karaer, S. Cavkaytar, I. Mert, U. Buyukkagnici, and S. Batioglu Cardiovascular risk factors in polycystic ovary syndrome J Obstet Gynaecol 30 2010 387 392
32. E. Cakal, Y. Ustun, Y. Engin-Ustun, M. Ozkaya, and M. Kilinç Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome Gynecol Endocrinol 27 2011 491 495
33. S.S. David, V.L. O'Shea, and S. Kundu Base-excision repair of oxidative DNA damage Nature 447 2007 941 950
34. V. Fenkci, S. Fenkci, M. Yilmazer, and M. Serteser Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease Fertil Steril 80 2003 123 127
35. F.F. Verit, and O. Erel Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters Gynecol Obstet Invest 65 2008 233 239
36. S. Rajendran, S.R. Willoughby, W.P. Chan, E.A. Liberts, T. Heresztyn, and M. Saha Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects Atherosclerosis 204 2009 509 514
37. M. Karadeniz, M. Erdoǧan, S. Tamsel, A. Zengi, G.E. Alper, and O. Caǧlayan Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances Exp Clin Endocrinol Diabetes 116 2008 231 235
38. J.L. Evans, B.A. Maddux, and I.D. Goldfine The molecular basis for oxidative stress-induced insulin resistance Antioxid Redox Signal 7 2005 1040 1052
39. M. Pollak Metformin and other biguanides in oncology: advancing the research agenda Cancer Prev Res (Phila) 3 2010 1060 1065
40. K. Hosono, H. Endo, H. Takahashi, M. Sugiyama, E. Sakai, and T. Uchiyama Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev Res (Phila) 3 2010 1077 1083
41. R.M. Memmott, J.R. Mercado, C.R. Maier, S. Kawabata, S.D. Fox, and P.A. Dennis Metformin prevents tobacco carcinogen-induced lung tumorigenesis Cancer Prev Res (Phila) 3 2010 1066 1076
42. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
43. G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, and J.M. Evans New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
44. H. Sova, L. Morin-Papunen, U. Puistola, and P. Karihtala Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndrome Fertil Steril 94 2010 2670 2673
45. C.Y. Ock, K.S. Hong, K.S. Choi, M.H. Chung, Y. Kim, and J.H. Kim A novel approach for stress-induced gastritis based on paradoxical anti-oxidative and anti-inflammatory action of exogenous 8-hydroxydeoxyguanosine Biochem Pharmacol 81 2011 111 122
46. N. Sakano, D.H. Wang, N. Takahashi, B. Wang, R. Sauriasari, S. Kanbara, and Sato Oxidative stress biomarkers and lifestyles in Japanese healthy people J Clin Biochem Nutr 44 2009 185 195
47. A. Mastalerz-Migas, A. Steciwko, M. Pokorski, I. Pirogowicz, J. Drobnik, and A. Bunio What influences the level of oxidative stress as measured by 8-hydroxy-2′-deoxyguanosine in patients on hemodialysis? J Physiol Pharmacol 57 2006 199 205